ERVW-1 and myeloid sarcoma: Clinical trials performed on MS patients with the antiretroviral integrase inhibitor, raltegravir, failed to see reduction in lesion count, progression, or inflammatory cytokine levels, suggesting HERV W-Env protein production is not targeted with this integrase (140).